🚀 ProPicks AI Hits +34.9% Return!Read Now

BRIEF-Transition Therapeutics provides update on type 2 diabetes drug candidate

Published 2016-04-18, 06:24 a/m
© Reuters.  BRIEF-Transition Therapeutics provides update on type 2 diabetes drug candidate
TTH
-

April 18 (Reuters) - Transition Therapeutics Inc TTH.TO
* Transition therapeutics provides update on type 2 diabetes
drug candidate TT401
* Received notification Eli Lilly will not elect to advance
diabetes drug candidate, TT401 into phase 3 development
* Royalty that Transition is eligible to receive on sales of
related Lilly compounds remains unaffected
* All TT401 development and commercialization rights will be
transferred to transition
* Transition Therapeutics Inc says provides update on type
2 diabetes drug candidate TT401
* Going forward, lilly will be eligible to receive a royalty
on future TT401 sales and a royalty on TT401 non-royalty income
* Under cos collaboration agreement, all TT401 development
and commercialization rights will be transferred to Transition

Source text for Eikon: ID:nCNWNtxHda
Further company coverage: TTH.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.